OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

• Published in: Annals of the Rheumatic Diseases Vol. 80; no. Suppl 1; pp. 102 - 103
• Main Authors: Spiera, R., Kuwana, M., Khanna, D., Hummers, L., Frech, T., Stevens, W., Gordon, J., Kafaja, S., Matucci-Cerinic, M., Distler, O., Lee, E.B., Levy, Y., Jun, J.B., Constantine, S., Dgetluck, N., White, B., Furst, D., Denton, C.
• Format: Journal Article
• Language: English; Japanese
• Published: Kidlington Elsevier B.V 01.06.2021; Elsevier BV; Elsevier Limited
• Subjects: Adverse events; Agonists; Animal models; Clinical trials; Demography; Fibrosis; General Biochemistry, Genetics and Molecular Biology; Grants; Immunological tolerance; Immunology; Immunology and Allergy; Mycophenolic acid; Pharmaceuticals; Placebos; Research funding; Rheumatology; Safety; Scleroderma; Systemic sclerosis

Lenabasum is an oral CB2 agonist that attenuates inflammation and fibrosis in SSc animal models and showed clinical benefit with acceptable safety in a Phase 2 trial in dcSSc. Test efficacy and safety of lenabasum in a Phase 3 trial in dcSSc. Subjects ≥18 years old with disease duration ≤ 6 years we...